Step Pharma, SAS

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Step Pharma, SAS sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Step Pharma, SAS: 2 sponsored US clinical trials, 2 recruiting.

Step Pharma, SAS sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, T-Cell, with 1 trials.

Mid-pack sponsor footprint

Step Pharma, SAS is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING Phase 1

Study of STP938 in Advanced Solid Tumours

NCT06297525
RECRUITING Phase 1

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

NCT05463263

Phase Distribution

PhaseTrial count
Phase 1 2

Therapeutic Areas

Lymphoma, T-Cell 1
Solid Tumor 1
Lymphoma, B-Cell 1

What is open in the Step Pharma, SAS pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Lymphoma, T-Cell (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Step Pharma, SAS: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Step Pharma, SAS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Step Pharma, SAS1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Step Pharma, SAS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Step Pharma, SAS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Step Pharma, SAS page

2 registered trials is a research-attention snapshot, not an endorsement of Step Pharma, SAS or any single study.

  • 2 of Step Pharma, SAS's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lymphoma, T-Cell is the condition Step Pharma, SAS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, T-Cell trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Step Pharma, SAS pipeline card: 2 registered trials from official public datasets.Report a data error.